Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.

Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V.

Eur J Endocrinol. 2015 Apr;172(4):403-13. doi: 10.1530/EJE-14-0837. Epub 2015 Jan 12.

PMID:
25583906
2.

Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.

Onder S, Ozturk Sari S, Yegen G, Sormaz IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y, Mete O.

Endocr Pathol. 2016 Jun;27(2):153-61. doi: 10.1007/s12022-016-9420-0.

PMID:
26951110
3.

Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.

Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK, Yang JH.

Thyroid. 2016 Jul;26(7):901-10. doi: 10.1089/thy.2015.0488. Epub 2016 Jun 6.

PMID:
27184112
4.

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M.

J Clin Endocrinol Metab. 2014 Jun;99(6):E1130-6. doi: 10.1210/jc.2013-4048. Epub 2014 Mar 11.

5.

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.

Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK.

Diagn Pathol. 2016 Feb 9;11:21. doi: 10.1186/s13000-016-0458-6.

6.

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.

Sun J, Zhang J, Lu J, Gao J, Ren X, Teng L, Duan H, Lin Y, Li X, Zhang B, Liang Z.

PLoS One. 2016 Apr 11;11(4):e0153319. doi: 10.1371/journal.pone.0153319. eCollection 2016.

7.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

8.

Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Oishi N, Kondo T, Nakazawa T, Mochizuki K, Inoue T, Kasai K, Tahara I, Yabuta T, Hirokawa M, Miyauchi A, Katoh R.

Endocr Pathol. 2017 Jun;28(2):103-111. doi: 10.1007/s12022-017-9470-y.

PMID:
28176151
9.

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.

Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.

PMID:
28323937
10.

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.

Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R, Hayashi T, Arakawa A, Yao T.

Virchows Arch. 2016 Dec;469(6):687-696. Epub 2016 Oct 7.

PMID:
27718012
11.

Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.

Vuong HG, Altibi AM, Duong UN, Ngo HT, Pham TQ, Tran HM, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T.

Tumour Biol. 2017 Oct;39(10):1010428317713913. doi: 10.1177/1010428317713913.

PMID:
29037127
12.

Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.

Sohn SY, Park WY, Shin HT, Bae JS, Ki CS, Oh YL, Kim SW, Chung JH.

Thyroid. 2016 May;26(5):672-82. doi: 10.1089/thy.2015.0527.

PMID:
26971368
13.

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.

Bu R, Siraj AK, Divya SP, Kong Y, Parvathareddy SK, Al-Rasheed M, Al-Obaisi KAS, Victoria IG, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS.

Int J Cancer. 2018 May 15;142(10):2028-2039. doi: 10.1002/ijc.31225. Epub 2017 Dec 29.

PMID:
29266240
14.

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y, Yang X, Zhao J, Du J, El-Naggar AK, Teng W, Xing M.

J Clin Endocrinol Metab. 2015 Apr;100(4):E632-7. doi: 10.1210/jc.2014-3606. Epub 2015 Jan 13.

15.

Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.

Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A.

Endocr Relat Cancer. 2015 Jun;22(3):419-29. doi: 10.1530/ERC-15-0057. Epub 2015 Apr 13.

16.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J.

J Clin Oncol. 2014 Sep 1;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094. Epub 2014 Jul 14.

17.

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P.

J Clin Endocrinol Metab. 2014 May;99(5):E754-65. doi: 10.1210/jc.2013-3734. Epub 2014 Jan 29.

18.

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.

Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O.

Oncotarget. 2016 Apr 5;7(14):18346-55. doi: 10.18632/oncotarget.7811.

19.

TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.

Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, Alzahrani AS.

Endocr Relat Cancer. 2015 Dec;22(6):901-8. doi: 10.1530/ERC-15-0396. Epub 2015 Sep 9.

PMID:
26354077
20.

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients.

Rusinek D, Pfeifer A, Krajewska J, Oczko-Wojciechowska M, Handkiewicz-Junak D, Pawlaczek A, Zebracka-Gala J, Kowalska M, Cyplinska R, Zembala-Nozynska E, Chekan M, Chmielik E, Kropinska A, Lamch R, Jurecka-Lubieniecka B, Jarzab B, Czarniecka A.

Int J Mol Sci. 2018 Sep 6;19(9). pii: E2647. doi: 10.3390/ijms19092647.

Supplemental Content

Support Center